Abuse of dominance, Commitments, European Commission, European Union, Excessive pricing

(DLA Piper Ireland), (DLA Piper UK), (DLA Piper Belgium), and (DLA Piper Romania)/ /Leave a comment

Back in April 2017, The Times ran a story detailing how a drug giant had a “secret plan” to destroy a cancer medicine unless large price rises were agreed to by national purchasing authorities.  A month later, the European Commission opened an investigation into Aspen.  Almost four years later in February 2021, it accepted commitments…

Commitments, European Commission, European Union, Excessive pricing, Pharmaceuticals

(DLA Piper Belgium), (DLA Piper Romania), (DLA Piper Ireland), and (DLA Piper Denmark)/ /Leave a comment

What are commitments? The recent effort by the Commission to settle the Aspen case suggests that commitment decisions are the preferred route to settle complex excessive pricing cases at EU-level.  Previous commitment cases where high prices have been at issue include Rambus, Standard & Poor’s and Gazprom.  The EU rules allow the Commission to make…